Theratechnologies Inc. (THTX)
1.72
0.06 (3.61%)
At close: Jan 14, 2025, 3:59 PM
1.80
4.94%
After-hours Jan 14, 2025, 05:12 PM EST
undefined% (undefined)
| Bid | 1.61 |
| Market Cap | 78.86M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.04 |
| PE Ratio (ttm) | -42.88 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.46 |
| Volume | 88,568 |
| Avg. Volume (20D) | 93,654 |
| Open | 1.65 |
| Previous Close | 1.66 |
| Day's Range | 1.61 - 1.72 |
| 52-Week Range | 1.08 - 2.18 |
| Beta | undefined |
About THTX
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant ...
Sector Healthcare
IPO Date Feb 13, 2009
Employees 103
Stock Exchange NASDAQ
Ticker Symbol THTX
Website https://www.theratech.com
Analyst Forecast
According to 1 analyst ratings, the average rating for THTX stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Theratechnologies Inc. is scheduled to release its earnings on Feb 19, 2025,
before market opens.
Analysts project revenue of $22.63M, reflecting a -3.51% YoY shrinking and earnings per share of 0.05, making a -162.50% decrease YoY.
Analysts project revenue of $22.63M, reflecting a -3.51% YoY shrinking and earnings per share of 0.05, making a -162.50% decrease YoY.
2 months ago ·
Source
+7.56%
Foghorn Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
3 months ago ·
Source
+3.28%
Theratechnologies shares are trading higher after the company reported better-than-expected Q3 GAAP EPS results.
